Post-menopausal osteoporosis and estrogens. Who should be treated and why

Area of Science:

• Endocrinology
• Bone Metabolism
• Women's Health

Background:

• Menopause-induced estrogen deficiency leads to skeletal calcium loss and increased fracture risk.
• Estrogen replacement therapy is known to prevent these postmenopausal changes.

Purpose of the Study:

• To evaluate the efficacy of different estrogen formulations in preventing bone loss.
• To define the appropriate use of hormone therapy in postmenopausal women.

Main Methods:

• Administration of daily doses of conjugated equine estrogen (0.625 mg), estradiol-17 beta (1 mg), or ethinyl estradiol (0.15 mg) to postmenopausal women.
• Observation of skeletal calcium balance and bone fracture incidence.

Main Results:

• All tested estrogen doses effectively prevented estrogen deficiency-related bone changes.
• Long-term safety data from large controlled studies are lacking.

Conclusions:

• Estrogen therapy is effective in preventing bone loss and fractures in postmenopausal women.
• Hormone treatment should be reserved for symptomatic individuals or those at high risk for osteoporosis.
• Risk factors for osteoporosis include fair skin, low body weight, smoking, heavy alcohol consumption, corticosteroid use, early menopause, and rheumatoid arthritis.